Madhav Dhodapkar

Summary

Affiliation: Yale University
Country: USA

Publications

  1. pmc Type II NKT Cells and Their Emerging Role in Health and Disease
    Madhav V Dhodapkar
    Section of Hematology, Department of Medicine, Yale School of Medicine, Yale University, New Haven CT 06510
    J Immunol 198:1015-1021. 2017
  2. pmc Immune Modulation in Hematologic Malignancies
    Madhav V Dhodapkar
    Departments of Internal Medicine Hematology Immunobiology, Yale University, New Haven, CT Yale Cancer Center, Yale University, New Haven, CT Electronic address
    Semin Oncol 42:617-25. 2015
  3. pmc Personalized immune-interception of cancer and the battle of two adaptive systems--when is the time right?
    Madhav V Dhodapkar
    Yale University School of Medicine, 333 Cedar Street, Box 208028, New Haven, CT 06510, USA
    Cancer Prev Res (Phila) 6:173-6. 2013
  4. pmc Vaccines targeting cancer stem cells: are they within reach?
    Madhav V Dhodapkar
    Departments of Medicine, Immunobiology and Pediatrics, Yale University, New Haven, CT, USA
    Cancer J 17:397-402. 2011
  5. pmc Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges
    Madhav V Dhodapkar
    Section of Hematology, Yale University, New Haven, CT 06510, USA
    Clin Immunol 140:160-6. 2011
  6. pmc Spontaneous and therapy-induced immunity to pluripotency genes in humans: clinical implications, opportunities and challenges
    Madhav V Dhodapkar
    Section of Hematology, Yale University, New Haven, CT 06510, USA
    Cancer Immunol Immunother 60:413-8. 2011
  7. pmc Immunity to stemness genes in human cancer
    Madhav V Dhodapkar
    Section of Hematology, Yale University, New Haven, CT 06510, USA
    Curr Opin Immunol 22:245-50. 2010
  8. pmc Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges
    Madhav V Dhodapkar
    Hematology Section, Yale University School of Medicine, New Haven, CT 06510, USA
    Front Biosci (Landmark Ed) 14:796-807. 2009
  9. pmc Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003
    Madhav V Dhodapkar
    Section of Hematology and Yale Cancer Center, Yale University, New Haven, CT 06510, USA
    Blood 113:793-6. 2009
  10. pmc Role of chaperones and FcgammaR in immunogenic death
    Madhav V Dhodapkar
    Section of Hematology, Yale University, New Haven, CT, USA
    Curr Opin Immunol 20:512-7. 2008

Research Grants

  1. Targeting myeloma via dendritic cells
    Madhav Dhodapkar; Fiscal Year: 2009

Collaborators

Detail Information

Publications16

  1. pmc Type II NKT Cells and Their Emerging Role in Health and Disease
    Madhav V Dhodapkar
    Section of Hematology, Department of Medicine, Yale School of Medicine, Yale University, New Haven CT 06510
    J Immunol 198:1015-1021. 2017
    ..An improved understanding of the biology of these cells and the ability to manipulate their function may be of therapeutic benefit in diverse disease conditions...
  2. pmc Immune Modulation in Hematologic Malignancies
    Madhav V Dhodapkar
    Departments of Internal Medicine Hematology Immunobiology, Yale University, New Haven, CT Yale Cancer Center, Yale University, New Haven, CT Electronic address
    Semin Oncol 42:617-25. 2015
    ....
  3. pmc Personalized immune-interception of cancer and the battle of two adaptive systems--when is the time right?
    Madhav V Dhodapkar
    Yale University School of Medicine, 333 Cedar Street, Box 208028, New Haven, CT 06510, USA
    Cancer Prev Res (Phila) 6:173-6. 2013
    ..We try to make the case to consider individualized approaches based on the genetic make-up of tumor cells and properties of the host response. Such strategies may be needed to optimally position the immune system to prevent cancers...
  4. pmc Vaccines targeting cancer stem cells: are they within reach?
    Madhav V Dhodapkar
    Departments of Medicine, Immunobiology and Pediatrics, Yale University, New Haven, CT, USA
    Cancer J 17:397-402. 2011
    ..Immunologic approaches targeting stemness-associated pathways in cancer may provide an important strategy for the prevention of diverse cancers, including those occurring in the context of regenerative therapies...
  5. pmc Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges
    Madhav V Dhodapkar
    Section of Hematology, Yale University, New Haven, CT 06510, USA
    Clin Immunol 140:160-6. 2011
    ..These results have set the stage for ongoing studies combining NKT activation with immune-modulatory drugs. Lessons learnt from these studies may inform the optimal application of human NKT based therapies in other settings as well...
  6. pmc Spontaneous and therapy-induced immunity to pluripotency genes in humans: clinical implications, opportunities and challenges
    Madhav V Dhodapkar
    Section of Hematology, Yale University, New Haven, CT 06510, USA
    Cancer Immunol Immunother 60:413-8. 2011
    ..Immunologic targeting of pathways associated with stemness has implications for both immune regulation of tumor growth as well as emerging regenerative therapies with embryonal stem cells...
  7. pmc Immunity to stemness genes in human cancer
    Madhav V Dhodapkar
    Section of Hematology, Yale University, New Haven, CT 06510, USA
    Curr Opin Immunol 22:245-50. 2010
    ..Immunologic targeting of pathways associated with stemness has implications for both immune regulation of tumor growth as well as regenerative therapies with embryonal stem cells...
  8. pmc Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges
    Madhav V Dhodapkar
    Hematology Section, Yale University School of Medicine, New Haven, CT 06510, USA
    Front Biosci (Landmark Ed) 14:796-807. 2009
    ..However several challenges need to be overcome in order to effectively harness the properties of these cells in the clinic...
  9. pmc Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003
    Madhav V Dhodapkar
    Section of Hematology and Yale Cancer Center, Yale University, New Haven, CT 06510, USA
    Blood 113:793-6. 2009
    ..001). These data provide novel insights into factors predicting long-term outcome in WM. This trial has been registered with www.cancer.gov under ID 4852904...
  10. pmc Role of chaperones and FcgammaR in immunogenic death
    Madhav V Dhodapkar
    Section of Hematology, Yale University, New Haven, CT, USA
    Curr Opin Immunol 20:512-7. 2008
    ..Understanding both these pathways of immunogenic cell death may yield novel approaches to regulate immunity...
  11. pmc Natural immunity to pluripotency antigen OCT4 in humans
    Kavita M Dhodapkar
    Department of Pediatrics, Yale University, New Haven, CT 06510, USA
    Proc Natl Acad Sci U S A 107:8718-23. 2010
    ..Harnessing natural immunity to this antigen may allow immune-based targeting of pluripotency-related pathways for prevention of cancers, including those in the setting of ES/IPS-based therapies...
  12. pmc Harnessing CD1d-restricted T cells toward antitumor immunity in humans
    Natalia Neparidze
    Section of Hematology, Yale University, New Haven, CT 06510, USA
    Ann N Y Acad Sci 1174:61-7. 2009
    ..Harnessing CD1d-restricted T cells in cancer may depend on regulating the balance between type I and II NKT cells and holds promise as a broad strategy for immune therapy of several cancers...
  13. ncbi request reprint The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells
    Carole L Berger
    Yale University, School of Medicine, Department of Dermatology and Laboratory Medicine, New Haven, CT 06510, USA
    Blood 99:2929-39. 2002
    ..In addition, the culture of CTCL cells will permit evaluation of therapies in vitro before clinical intervention, thereby improving safety and efficacy...
  14. pmc A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"
    Lisa H Butterfield
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, 15213, USA
    J Transl Med 6:81. 2008
    ..This foreword provides an overview of the task force and invites feedback from readers that might be incorporated in the discussions and in the final document...
  15. ncbi request reprint Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma
    Hani Hassoun
    Division of Hematologic Oncology, Department of Medicine, Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 132:155-61. 2006
    ..AD-TD administered with low dose aspirin for deep vein thrombosis prophylaxis was well tolerated and yielded a high response rate with minimal treatment-related morbidity...
  16. pmc Waldenstrom's macroglobulinemia: Recent advances in biology and therapy
    Natalia Neparidze
    Yale University, New Haven, CT 06510, USA
    Clin Adv Hematol Oncol 7:677-81, 687-90. 2009
    ..This report provides an update on recent advances in biology and treatment of this disease...

Research Grants1

  1. Targeting myeloma via dendritic cells
    Madhav Dhodapkar; Fiscal Year: 2009
    ..abstract_text> ..